174 Does addition of erythropoietic stimulating agents (ESAs) improve the outcome of higher-risk MDS patients treated with azacitidine (AZA)?
Saved in:
| Title: | 174 Does addition of erythropoietic stimulating agents (ESAs) improve the outcome of higher-risk MDS patients treated with azacitidine (AZA)? |
|---|---|
| Authors: | Itzykson, R., Thepot, S., Beyne-Rauzy, O., Ame, S., Isnard, F., Salanoubat, C., Taksin, A.-L., Chelgoum, Y., Quesnel, B., Malfuson, J.-V., Legros, L., Vey, N., Turlure, P., Gardin, C., Boehrer, S., Ades, L., Fenaux, P. |
| Source: | Leukemia Research. Jan2011 Supplement 1, Vol. 35, pS68-S68. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
